Novavax (NVAX) Free Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Novavax (NVAX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 38.94% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 96.00% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 152.82% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 31.57% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 58.53% |
| 10 | Novavax | 1.67 Bn | 951.85 Mn | 42.45 Mn | 42.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42.66% |
| Mar 31, 2026 | 81.99% |
| Dec 31, 2025 | 76.29% |
| Sep 30, 2025 | 172.79% |
| Jun 30, 2025 | -141.10% |
| Mar 31, 2025 | -106.89% |
| Dec 31, 2024 | 5.67% |
| Sep 30, 2024 | -152.86% |
| Jun 30, 2024 | 274.05% |
| Mar 31, 2024 | 73.82% |
| Dec 31, 2023 | -31.80% |
| Sep 30, 2023 | 8.72% |
| Jun 30, 2023 | 8.48% |
| Mar 31, 2023 | -227.90% |
| Dec 31, 2022 | 60.41% |
| Sep 30, 2022 | 58.96% |
| Jun 30, 2022 | -251.23% |
| Mar 31, 2022 | -116.22% |
| Dec 31, 2021 | -108.76% |
| Sep 30, 2021 | -913.81% |